Innovent Biologics jumps most in five months on Eli Lilly deal
** Shares of Innovent Biologics 1801.HK jump 8.6% to HK$86.3, set for its biggest one-day pct gain since September 1 ** Innovent has struck a new deal with Eli Lilly LLY.N to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 mln upfront and as much as $8.5 bln more if milestones are met ** YTD, stock up 11.3%, Hang Seng Biotech Index .HSBIO up 9.5% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis